Formerly the ABMTRR ANZTCT Registry The ANZTCT Registry The registry was established in 1992 and was previously known as the ABMTRR (Australasian Bone Marrow Transplant Recipient Registry). It was rebranded in its 30th anniversary year to better reflect its operation under the auspices of Australia and New Zealand Transplant and Cellular Therapies (ANZTCT), previously the Bone Marrow Transplant Society of Australia and New Zealand. The registry records details of bone marrow, peripheral blood and cord blood stem cell transplants and other cellular therapies including CAR-T throughout Australia and New Zealand. The registry is a Commonwealth-funded Clinical Quality Registry. Clinical data Our Annual Data Summary reports on transplant activity, trends and outcomes for autologous and allogeneic transplants performed in Australia and New Zealand. Registry data supports monitoring of outcomes, best clinical practice and the development of guidelines. The TGA and MSAC recommended data collection and reporting by ANZTCT Registry as a condition of approval of commercial CAR-T products. The registry also has the facility to collect these data for other cellular therapy products in both the standard treatment and clinical trial settings. ANZTCT Registry Accrual Data Quality and Benchmarking The registry provides data to hospitals for internal quality programs and to assist with accreditation requirements for stem cell transplant and cell therapy services. Accrediting bodies such as FACT and JACIE require benchmarking against national and international standards. ANZTCT Registry is the only source of this analysis for Australia and New Zealand, and now provides hospital reports for all contributing centres. Research Support ANZTCT Registry data are regularly used for scene setting and feasibility to help plan research projects. Retrospective reviews and analyses of registry data are presented at local and international conferences and may lead to publications in peer reviewed journals. Prospective studies are also supported by the registry. Transplant and Cellular Therapies Services Planning With close to full enumeration of these complex procedures, ANZTCT Registry can provide data to help prioritise resource allocation for these services, such as staffing, laboratory equipment, short term patient care requirements and services for long term survivors. Contributing Centers The Registry Team Ms Leonie Wilcox Manager, Registry Board Appointed Director Ms Leonie Wilcox Manager, Registry Ms Leonie Wilcox (RN,MN, BSc) has been the manager of the Australia and New Zealand Transplant and Cellular Therapies Registry (formerly ABMTRR) since 2006. Over this time, she has seen its growth and development as a clinical quality registry, acquisition of Commonwealth funding and inclusion of the national CAR-T registry. She has a passion for accurate data as the backbone for clinical quality monitoring and improvement and continues to support the TCT community in achieving its goals in providing high quality data driven care. Donna Aarons Data Coordinator/Data Operations Lead Steven Tran Data Analyst/Technical Lead Banafsheh Moradmand-Badie Project Officer Zulekha Khan Project Officer Registry Annual Data Summary 2022 Every year the ABMTRR produces an Annual Data Summary, which describes the latest transplant activity in Australia and New Zealand. Over time there have been changes in the types of transplants performed, diseases being treated, age at transplant and stem cell source. Some survival data are also included. The Annual Data Summary is provided free of charge to contributing clinicians, and is available for purchase by other interested parties. Bone Marrow Transplants Haemopoietic stem cell transplants (HSCT), often referred to as ‘bone marrow transplants’ or ‘blood and marrow transplants’ (BMT), are used to treat a range of both haematological and non-haematological malignancies and other serious blood conditions in adults and children. Indications may include acute and chronic leukaemias, lymphoma, multiple myeloma, solid tumours such as medulloblastoma and neuroblastoma, and other conditions such as aplastic anaemia and immunodeficiencies. The stem cells may come from bone marrow, peripheral blood or cord blood. Transplants can be autologous, where the patient’s own stem cells are harvested and then returned after high-dose conditioning chemotherapy, or allogeneic, where the stem cells come from a donor. Allogeneic donors may be related to the patient, such as a sibling or parent, or unrelated. Unrelated donors are sourced from donor registries and cord blood banks worldwide. To find out about becoming a donor, please visit the ABMDR website.
Ms Leonie Wilcox Manager, Registry Board Appointed Director Ms Leonie Wilcox Manager, Registry Ms Leonie Wilcox (RN,MN, BSc) has been the manager of the Australia and New Zealand Transplant and Cellular Therapies Registry (formerly ABMTRR) since 2006. Over this time, she has seen its growth and development as a clinical quality registry, acquisition of Commonwealth funding and inclusion of the national CAR-T registry. She has a passion for accurate data as the backbone for clinical quality monitoring and improvement and continues to support the TCT community in achieving its goals in providing high quality data driven care.